



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

APR 3 2003

Re: Zetia
Docket No.: 03E-0035

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 2327
Arlington, VA 22202

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 37,721, filed by Schering Corporation, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Zetia, the human drug product claimed by the patent.

The total length of the regulatory review period for Zetia is 1,983 days. Of this time, 1,680 days occurred during the testing phase and 303 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: May 23, 1997.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on May 23, 1997.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: December 27, 2001.

FDA has verified the applicant's claim that the new drug application (NDA) for Zetia (NDA 21-445) was initially submitted on December 27, 2001.


3. The date the application was approved: October 25, 2002.

FDA has verified the applicant's claim that NDA 21-445 was approved on October 25, 2002.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Jane A. Axelrad".

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Thomas D. Hoffman
Schering Corporation
Patent Department, K-6-1 1990
2000 Galloping Hill Rd
Kenilworth, NJ 07033-0530